Scholarlink

Objective <p>To investigate the effect of belimumab combined with conventional therapy on natural killer (NK) cells counts and its correlation with clinical response in childhood systemic lupus erythematosus (cSLE).</p> Methods <p>A retrospective analysis was conducted on 46 cSLE patients treated with belimumab plus standard therapy for 48 weeks. NK cell counts, complement levels, SLEDAI-2&#xa0;K scores, and steroid doses were assessed at baseline, 24, and 48 weeks. Statistical analyses included paired t-test, Wilcoxon test, Pearson/Spearman correlation, and minimal clinically important difference (MCID) calculation.</p> Results <p>NK cell counts increased from 72.0 ± 56.6 cells/µL at baseline to 185.6 ± 84.5 cells/µL at week 48 (<i>P</i> &lt; 0.05). Complement C3 and C4 levels also improved significantly. SLEDAI-2&#xa0;K scores decreased from 16.4 to 2.1 (<i>P</i> &lt; 0.05), with 88.1% achieving low disease activity. Steroid dose was reduced in over 90% of patients. NK cell increase strongly correlated with both complement recovery (ρ = 0.68, <i>P</i> &lt; 0.05) and disease activity improvement (ρ = 0.69, <i>P</i> &lt; 0.05).</p> Conclusions <p>Belimumab combined with conventional therapy may enhance NK cell counts, improve serological and clinical outcomes, and facilitate steroid tapering in cSLE. Further prospective controlled studies are needed to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of belimumab combined with conventional treatment on NK cell count in childhood systemic lupus erythematosus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月22日

查看全文
  • Hongjun Han,
  • Qihua Feng,
  • Xiaoxiang Song,
  • Yue Min

摘要

Objective

To investigate the effect of belimumab combined with conventional therapy on natural killer (NK) cells counts and its correlation with clinical response in childhood systemic lupus erythematosus (cSLE).

Methods

A retrospective analysis was conducted on 46 cSLE patients treated with belimumab plus standard therapy for 48 weeks. NK cell counts, complement levels, SLEDAI-2 K scores, and steroid doses were assessed at baseline, 24, and 48 weeks. Statistical analyses included paired t-test, Wilcoxon test, Pearson/Spearman correlation, and minimal clinically important difference (MCID) calculation.

Results

NK cell counts increased from 72.0 ± 56.6 cells/µL at baseline to 185.6 ± 84.5 cells/µL at week 48 (P < 0.05). Complement C3 and C4 levels also improved significantly. SLEDAI-2 K scores decreased from 16.4 to 2.1 (P < 0.05), with 88.1% achieving low disease activity. Steroid dose was reduced in over 90% of patients. NK cell increase strongly correlated with both complement recovery (ρ = 0.68, P < 0.05) and disease activity improvement (ρ = 0.69, P < 0.05).

Conclusions

Belimumab combined with conventional therapy may enhance NK cell counts, improve serological and clinical outcomes, and facilitate steroid tapering in cSLE. Further prospective controlled studies are needed to confirm these findings.